Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LITAF domain-containing proteins, including human LITAF (LPS-induced TNF-activating factor, also known as SIMPLE), represent a conserved family of endosome-associated, monotopic integral membrane proteins, characterized by a C-terminal LITAF (or SIMPLE-like) domain that integrates into membranes via a hydrophobic segment stabilized by zinc finger-like cysteine-rich regions[1][3]. These proteins are critical for multivesicular body (MVB) sorting, exosome formation, and the recruitment of the ESCRT (endosomal sorting complexes required for transport) machinery via specific binding motifs (e.g., PSAP, PPXY)[1][3]. Mutations in the LITAF domain that disrupt membrane association lead to Charcot-Marie-Tooth disease type 1C, highlighting their essential role in peripheral nerve function[1][3]. LITAF domain proteins are involved in membrane repair by promoting ESCRT-mediated extrusion of damaged membrane via extracellular vesicles, protecting against cell death in the context of membrane-damaging agents such as bacterial toxins and endogenous pore-forming proteins[3]. In plants, LITAF domain proteins anchor in the plasma membrane and negatively regulate programmed cell death, further illustrating their conserved membrane-localization and protein interaction roles[2]. Key points: - This entry is **not a classical drug target** like a receptor, enzyme, or transporter; rather, it is a structural/membrane trafficking protein[1][3]. - No known drugs, biomarkers, or mechanisms of action involving direct pharmacological targeting are reported. - "LITAF domain-containing protein" is a *domain/family* designation, not a single protein, and is not the standard for direct therapeutic targeting (the most relevant human protein is commonly called "LITAF" or "SIMPLE")[1][3]. - The provided names are generic for any protein harboring a LITAF domain and thus **do not refer to a unique molecular entity**; human LITAF is a well-characterized member. - Consider searching for "LITAF" or "SIMPLE" if you are interested in the canonical human target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LITAF domain-containing protein.